Drug Profile
Trandolapril/verapamil
Alternative Names: Ocadrik; Tarka; Verapamil/trandolaprilLatest Information Update: 22 Jan 2013
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer AbbVie; Sanofi
- Class Antihypertensives; Indoles
- Mechanism of Action ACE inhibitors; Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Hypertension
Most Recent Events
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 03 Jun 2004 Aventis granted Abbott Laboratories the remaining commercial rights for trandolapril, except in Japan